Schindellegi, Switzerland – 29 December 2025 Trifork Group AGCompany announcement no. 61/2025 Weekly report on share buyback On 22 December 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour regulation). The share buyback program runs from 23 December 2025 up to and including no later than 26 February 2026. For details, please see company announcement no. 58 of 22 December 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 219,735 treasury shares, corresponding to 1.1% of the share capital. Under the program, the following transactions...

Albert Saporta, Co-CIO GAM AlternativesAlbert Saporta, Co-CIO GAM Alternatives, Group CEO GAM Holding AG, GAM Investment Management (Switzerland) AG, albert.saporta@gam.comRandel Freeman, Co-CIO GAM AlternativesRandel Freeman, Co-CIO GAM Alternatives, GAM InvestmentsLondon / Zurich, 29 December 2025 PRESS RELEASE Portfolio managers of three GAM-managed special situations funds publish open letter on Yutaka Giken tender offer Albert Saporta and Randel Freeman call for full transparency on the fairness analysis and a materially improved price to protect minority shareholders On the 22 December 2025 the portfolio managers of the GAM Japan Special Situations Fund, the GAM Special Situations Fund and the GAM Global Opportunities Fund published an open letter to the Chairman of Yutaka Giken Co., Ltd., regarding the proposed...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,986,009 655.96 1,958,706,33522 December 2025 15,000 857.17 12,857,58223...

Rights plan protects the Company and its stockholders from a change of control without a control premium Amended and Restated Bylaws ensure orderly and informed consent solicitation LOUISVILLE, CO, Dec. 28, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC) (the “Company” or “BNC”), which manages the world’s largest corporate treasury of BNB, today announced that its Board of Directors (the “Board”) unanimously adopted a limited duration stockholder rights agreement (the “Rights Plan”) and amended and restated bylaws (the “Amended and Restated Bylaws”) on December 26, 2025. The Board adopted the Rights Plan and the Amended and Restated Bylaws following the formation of a stockholder group (together, the “YZi Labs Group”) by YZILabs Management Ltd. (“YZi Labs”) that seeks control of the Company. As previously confirmed by...

PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) — Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company. Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how,...

Global semiconductor leader licenses Weebit’s non-volatile memory (NVM) IP for some of its products HOD HASHARON, Israel, Dec. 28, 2025 (GLOBE NEWSWIRE) — Weebit Nano Limited (ASX:WBT) (Weebit or Company), a leading developer and licensor of advanced memory technologies for the global semiconductor industry, announced it has licensed its resistive random access memory (ReRAM) technology to Texas Instruments (TI), a global semiconductor company that designs, manufactures and sells analog and embedded processing chips. Under the terms of the agreement, Weebit’s ReRAM technology will be integrated into TI’s advanced process nodes for embedded processing semiconductors. The agreement includes IP licensing, technology transfer, design and qualification of Weebit ReRAM in TI’s process technologies. Weebit ReRAM is a low-power, cost-effective...

MONTREAL, Dec. 27, 2025 (GLOBE NEWSWIRE) — Senvest Capital Inc. (the “Corporation” or “Senvest”) (TSX: SEC) announces with profound sadness the passing of its founder and long-time leader, Victor Mashaal, who served as President, Chief Executive Officer, and Chairman of the Board of Directors. Victor passed away at the age of 87 following a brief illness. He was a deeply respected and admired leader and a mentor to the entire Senvest family. He will be greatly missed. Richard Mashaal, Director and Vice-President of the Corporation, stated: “We all mourn the loss of a great man. My father founded the Corporation in 1968. The firm began with an initial investment of $10,000 to purchase the Canadian rights to Sensormatic Electronics Corporation’s anti-shoplifting products. He pioneered this industry in Canada, as well as the Canadian...

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex BlaniaTOKYO, Dec. 26, 2025 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), a diversified healthcare company, is collaborating with World Foundation and Tools for Humanity to deploy Proof of Human technologies such as World ID throughout Japan. The World project was co-created by Sam Altman and Alex Blania. In preparation for the full-scale rollout of the World project in Japan, MEDIROM has entered into a Master Service Agreement (“MSA”) with Tools for Humanity (“TFH”) and World Foundation (“WF”). Under the MSA, the MEDIROM Group will be responsible for the operation of “Proof of Human” verification locations in Japan. This...

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were sold at a price of USD$7.50 per Common Share. Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis). Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other...

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees. The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™...